Mereo BioPharma Group plc (MREO): Shareholders' Equity

Annual figures by period end, from SEC filings.

$40.92M
As of 2025-12-31
$28.65M
As of 2026-06-30
-7.3%
3-year compound annual growth
$60.97M2022-12-31: $51.40M2023-12-31: $50.54M2024-12-31: $60.97M2025-12-31: $40.92M$40.92M
2022-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$40.92M-32.9%2026-03-19, Balance as of period end
2024-12-31$60.97M+20.6%2026-03-19, Balance as of period end
2023-12-31$50.54M-1.7%2025-03-26, Balance as of period end
2022-12-31$51.40Mn/a2024-03-27, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Mereo BioPharma Group plc (MREO)2025-12-31$40.92M-32.9%
Lipella Pharmaceuticals Inc. (LIPO)2024-12-31$1.92M-39.0%
Quantum Cyber N.V. (QUCY)2025-12-31$641.6K-89.3%
Silence Therapeutics plc (SLN)2025-12-31$62.30M-53.5%
Yarrow Bioscience, Inc. (YARW)2025-12-31$27.77M-46.7%
Scienture Holdings, Inc. (SCNX)2025-12-31$70.12M-11.3%
PMGC Holdings Inc. (ELAB)2025-12-31$7.84M+17.7%
Vaccinex, Inc. (VCNX)2024-12-31-$2.49Mn/m
Medicinova Inc (MNOV)2025-12-31$41.59M-20.8%

Compare MREO, LIPO, QUCY, SLN side by side · Screen every company in Pharmaceutical Preparations ↗